JLE

Hépato-Gastro & Oncologie Digestive

MENU

Pronostic and predictive value of visceral fat in gastrointestinal cancerology Volume 28, issue 4, Avril 2021

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 CHRU Hôpitaux de Tours, Hôpital Trousseau, Service d’hépato-gastro entérologie, Avenue de la République, 37170 Chambray-lès-Tours
2 CHRU Hôpitaux de Tours, Hôpital Bretonneau, Centre de Données Clinique, 2 Boulevard Tonnellé, 37000 Tours
3 CHRU Hôpitaux de Tours, Hôpital Trousseau, Service de chirurgie digestive, Avenue de la République, 37170 Chambray-lès-Tours
4 Université François Rabelais, Tours
5 CHRU Hôpitaux de Tours, Hôpital Trousseau, Service de radiologie, Avenue de la République, 37170 Chambray-lès-Tours
* Correspondance

Visceral fat is the fat contained in the peritoneal cavity. Visceral fat accumulation causes metabolic disorders and diseases such as metabolic syndrome, myocardial infarction or cancer. These manifestations are related to physiopathological mechanisms involved via hormones and cytokines promoting angiogenesis, cell proliferation and inhibiting apoptosis. Leptin, TNFα, PAI-1 and IL-6 are part of those hormones and cytokines. Abdominal CT is the gold standard to determine visceral fat area. One cross-sectional scan obtained at the umbilicus or L3 level is sufficient. In gastrointestinal oncology, few studies evaluate the prognostic value of visceral fat. Most of them describe a pejorative role of visceral obesity. The increase of obesity prevalence and the resulting complications should prompt us to pay more attention to this emerging prognostic and predictive factor.